Jean M Addington

List of Publications by Year
in descending order

317 papers	23,843 citations	11908 72 h-index	10679 143 g-index
353 all docs	353 docs citations	353 times ranked	14023 citing authors

#	Article	IF	Citations
1	Characterizing sustained social anxiety in individuals at clinical high risk for psychosis: trajectory, risk factors, and functional outcomes. Psychological Medicine, 2023, 53, 3644-3651.	2.7	5
2	Family communication and the efficacy of family focused therapy in individuals at clinical high risk for psychosis with comorbid anxiety. Microbial Biotechnology, 2023, 17, 281-289.	0.9	1
3	Childhood trauma and amygdala nuclei volumes in youth at risk for mental illness. Psychological Medicine, 2022, 52, 1192-1199.	2.7	22
4	North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description. Schizophrenia Research, 2022, 243, 262-267.	1.1	39
5	Life Event Stress and Reduced Cortical Thickness in Youth at Clinical High Risk for Psychosis and Healthy Control Subjects. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2022, 7, 171-179.	1.1	2
6	Bullying and social functioning, schemas, and beliefs among youth at clinical high risk for psychosis. Microbial Biotechnology, 2022, 16, 281-288.	0.9	4
7	Sleep Disturbance in Individuals at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 111-121.	2.3	15
8	Individualized Prediction of Prodromal Symptom Remission for Youth at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 395-404.	2.3	7
9	Negative symptoms: associations with defeatist beliefs, self-efficacy, and maladaptive schemas in youth and young adults at-risk for psychosis. Behavioural and Cognitive Psychotherapy, 2022, 50, 298-311.	0.9	3
10	Cerebello-limbic functional connectivity patterns in youth at clinical high risk for psychosis. Schizophrenia Research, 2022, 240, 220-227.	1.1	6
11	Bullying in clinical high risk for psychosis participants from the NAPLS-3 cohort. Social Psychiatry and Psychiatric Epidemiology, 2022, 57, 1379-1388.	1.6	4
12	The associations between area-level residential instability and gray matter volumes from the North American Prodrome Longitudinal Study (NAPLS) consortium. Schizophrenia Research, 2022, 241, 1-9.	1.1	8
13	Longitudinal impact of trauma in the North American Prodrome Longitudinal Studyâ€ƒ. Microbial Biotechnology, 2022, 16, 1211-1216.	0.9	0
14	Family history of psychosis in youth at clinical high risk: A replication study. Psychiatry Research, 2022, 311, 114480.	1.7	3
15	Cognitive-Behavioral Social Skills Training Adapted for Youth at Clinical High Risk for Psychosis. Journal of Cognitive Psychotherapy, 2022, , JCP-2021-0029.R1.	0.2	1
16	Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis. Molecular Psychiatry, 2022, 27, 3670-3678.	4.1	13
17	Mismatch Negativity in Response to Auditory Deviance and Risk for Future Psychosis in Youth at Clinical High Risk for Psychosis. JAMA Psychiatry, 2022, 79, 780.	6.0	21
18	The Association Between Neighborhood Poverty and Hippocampal Volume Among Individuals at Clinical High-Risk for Psychosis: The Moderating Role of Social Engagement. Schizophrenia Bulletin, 2022, 48, 1032-1042.	2.3	9

#	Article	IF	Citations
19	Outcomes During and After Early Intervention Services for First-Episode Psychosis: Results Over 5 Years From the RAISE-ETP Site-Randomized Trial. Schizophrenia Bulletin, 2022, 48, 1021-1031.	2.3	7
20	Clinical staging for youth atâ€risk for serious mental illness: A longitudinal perspective. Microbial Biotechnology, 2021, 15, 1188-1196.	0.9	6
21	Associations between childhood adversity, cognitive schemas and attenuated psychotic symptoms. Microbial Biotechnology, 2021, 15, 818-827.	0.9	10
22	Depression, family interaction and family intervention in adolescents at clinicalâ€high risk for psychosis. Microbial Biotechnology, 2021, 15, 360-366.	0.9	1
23	Cross-paradigm connectivity: reliability, stability, and utility. Brain Imaging and Behavior, 2021, 15, 614-629.	1.1	7
24	Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. Schizophrenia Research, 2021, 227, 10-17.	1.1	28
25	Pilot aerobic exercise intervention for youth atâ€risk for serious mental illness. Microbial Biotechnology, 2021, 15, 547-553.	0.9	5
26	Substance use in youth atâ€risk for serious mental illness. Microbial Biotechnology, 2021, 15, 634-641.	0.9	1
27	Selection for psychosocial treatment for youth at clinical high risk for psychosis based on the North American Prodrome Longitudinal Study individualized risk calculator. Microbial Biotechnology, 2021, 15, 96-103.	0.9	9
28	Depression: An actionable outcome for those at clinical high-risk. Schizophrenia Research, 2021, 227, 38-43.	1.1	7
29	Social decline in the psychosis prodrome: Predictor potential and heterogeneity of outcome. Schizophrenia Research, 2021, 227, 44-51.	1.1	12
30	Concordance and factor structure of subthreshold positive symptoms in youth at clinical high risk for psychosis. Schizophrenia Research, 2021, 227, 72-77.	1.1	4
31	Embracing heterogeneity creates new opportunities for understanding and treating those at clinical-high risk for psychosis. Schizophrenia Research, 2021, 227, 1-3.	1.1	10
32	Incorporating cortisol into the NAPLS2 individualized risk calculator for prediction of psychosis. Schizophrenia Research, 2021, 227, 95-100.	1.1	17
33	LooseLeaf, a Mobile-Based Application to Monitor Cannabis Use and Cannabis-Related Experiences for Youth at Clinical High-Risk for Psychosis: Development and User Acceptance Testing. International Journal of Human-Computer Interaction, 2021, 37, 501-511.	3.3	1
34	Personality and risk for serious mental illness. Microbial Biotechnology, 2021, 15, 133-139.	0.9	5
35	Discriminatory experiences predict neuroanatomical changes and anxiety among healthy individuals and those at clinical high risk for psychosis. NeuroImage: Clinical, 2021, 31, 102757.	1.4	8
36	Longitudinal Trends in Medication Treatment for Youth At-Risk for Serious Mental Illness. Canadian Journal of Psychiatry, 2021, 66, 418-420.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Cognitive behavioural social skills training: Methods of a randomized controlled trial for youth at risk of psychosis. Microbial Biotechnology, 2021, 15, 1626-1636.	0.9	12
38	Abnormally Large Baseline P300 Amplitude Is Associated With Conversion to Psychosis in Clinical High Risk Individuals With a History of Autism: A Pilot Study. Frontiers in Psychiatry, 2021, 12, 591127.	1.3	10
39	The associations between migrant status and ethnicity and the identification of individuals at ultra-high risk for psychosis and transition to psychosis: a systematic review. Social Psychiatry and Psychiatric Epidemiology, 2021, 56, 1923-1941.	1.6	8
40	Assessing social functioning in youth at clinical high-risk for psychosis. Schizophrenia Research, 2021, 228, 188-189.	1.1	0
41	The Canadian Network for Research in Schizophrenia and Psychoses: A Nationally Focused Approach to Psychosis and Schizophrenia Research. Canadian Journal of Psychiatry, 2021, , 070674372110091.	0.9	2
42	Visual cortical plasticity and the risk for psychosis: An interim analysis of the North American Prodrome Longitudinal Study. Schizophrenia Research, 2021, 230, 26-37.	1.1	4
43	White matter changes in psychosis risk relate to development and are not impacted by the transition to psychosis. Molecular Psychiatry, 2021, 26, 6833-6844.	4.1	15
44	White matter microstructure in youth at risk for serious mental illness: A comparative analysis. Psychiatry Research - Neuroimaging, 2021, 312, 111289.	0.9	4
45	Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort. Biological Psychiatry, 2021, 90, 632-642.	0.7	32
46	Social functioning and brain imaging in individuals at clinical high-risk for psychosis: A systematic review. Schizophrenia Research, 2021, 233, 3-12.	1.1	4
47	Familyâ€focused therapy for individuals at high clinical risk for psychosis: A confirmatory efficacy trial. Microbial Biotechnology, 2021, , .	0.9	1
48	Anxiety in youth at clinical high-risk for psychosis: A two-year follow-up. Schizophrenia Research, 2021, 236, 87-88.	1.1	1
49	The association between migrant status and transition in an ultra-high risk for psychosis population. Social Psychiatry and Psychiatric Epidemiology, 2021, 56, 943-952.	1.6	5
50	Genetic and clinical analyses of psychosis spectrum symptoms in a large multiethnic youth cohort reveal significant link with ADHD. Translational Psychiatry, 2021, 11, 80.	2.4	11
51	Association between residential instability at individual and area levels and future psychosis in adolescents at clinical high risk from the North American Prodrome Longitudinal Study (NAPLS) consortium. Schizophrenia Research, 2021, 238, 137-144.	1.1	7
52	Adapting Evidence-Based Early Psychosis Intervention Services for Virtual Delivery: Protocol for a Pragmatic Mixed Methods Implementation and Evaluation Study. JMIR Research Protocols, 2021, 10, e34591.	0.5	1
53	Depression Predicts Global Functional Outcomes in Individuals at Clinical High Risk for Psychosis. Psychiatric Research and Clinical Practice, 2021, 3, 163-171.	1.3	4
54	Progressive reconfiguration of resting-state brain networks as psychosis develops: Preliminary results from the North American Prodrome Longitudinal Study (NAPLS) consortium. Schizophrenia Research, 2020, 226, 30-37.	1.1	36

#	ARTICLE	IF	CITATIONS
55	Stress perception following childhood adversity: Unique associations with adversity type and sex. Development and Psychopathology, 2020, 32, 343-356.	1.4	25
56	Telehealth interventions for schizophrenia-spectrum disorders and clinical high-risk for psychosis individuals: A scoping review. Journal of Telemedicine and Telecare, 2020, 26, 14-20.	1.4	80
57	Characterizing Covariant Trajectories of Individuals at Clinical High Risk for Psychosis Across Symptomatic and Functional Domains. American Journal of Psychiatry, 2020, 177, 164-171.	4.0	34
58	Social and role functioning in youth at risk of serious mental illness. Microbial Biotechnology, 2020, 14, 463-469.	0.9	8
59	Polygenic Risk Score Contribution to Psychosis Prediction in a Target Population of Persons at Clinical High Risk. American Journal of Psychiatry, 2020, 177, 155-163.	4.0	90
60	Sleep disturbances in youth atâ€risk for serious mental illness. Microbial Biotechnology, 2020, 14, 373-378.	0.9	14
61	Attrition rates in trials for adolescents and young adults at clinical highâ€risk for psychosis: A systematic review and metaâ€analysis. Microbial Biotechnology, 2020, 14, 515-527.	0.9	18
62	Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. Neuropsychopharmacology, 2020, 45, 283-291.	2.8	37
63	Predictive validity of conversion from the clinical high risk syndrome to frank psychosis. Schizophrenia Research, 2020, 216, 184-191.	1.1	22
64	Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review. Social Psychiatry and Psychiatric Epidemiology, 2020, 55, 527-537.	1.6	33
65	Trauma in Youth At-Risk for Serious Mental Illness. Journal of Nervous and Mental Disease, 2020, 208, 70-76.	0.5	7
66	Duration of the psychosis prodrome. Schizophrenia Research, 2020, 216, 443-449.	1.1	16
67	Evidence of Slow Neural Processing, Developmental Differences and Sensitivity to Cannabis Effects in a Sample at Clinical High Risk for Psychosis From the NAPLS Consortium Assessed With the Human Startle Paradigm. Frontiers in Psychiatry, 2020, 11, 833.	1.3	4
68	Aerobic exercise and hippocampal change in youth at risk of serious mental illness. Psychiatry Research - Neuroimaging, 2020, 305, 111199.	0.9	0
69	Brain changes associated with negative symptoms in clinical high risk for psychosis: A systematic review. Neuroscience and Biobehavioral Reviews, 2020, 118, 367-383.	2.9	7
70	Progression from being at-risk to psychosis: next steps. NPJ Schizophrenia, 2020, 6, 27.	2.0	39
71	Functional imaging in youth at risk for transdiagnostic serious mental illness: Initial results from the PROCAN study. Microbial Biotechnology, 2020, 15, 1276-1291.	0.9	3
72	Reliability of mismatch negativity event-related potentials in a multisite, traveling subjects study. Clinical Neurophysiology, 2020, 131, 2899-2909.	0.7	6

#	Article	IF	Citations
73	White Matter Connectivity in Youth at Risk for Serious Mental Illness: A Longitudinal Analysis. Psychiatry Research - Neuroimaging, 2020, 302, 111106.	0.9	4
74	Stressor-Cortisol Concordance Among Individuals at Clinical High-Risk for Psychosis: Novel Findings from the NAPLS Cohort. Psychoneuroendocrinology, 2020, 115, 104649.	1.3	21
75	Stability of mismatch negativity event†related potentials in a multisite study. International Journal of Methods in Psychiatric Research, 2020, 29, e1819.	1.1	10
76	A mobile-based app to monitor cannabis use among youth at clinical high risk (CHR) for psychosis: Feasibility and acceptability of LooseLeaf. Schizophrenia Research, 2020, 222, 505-506.	1.1	1
77	Indicated prevention in psychosis risk—psychological approaches. , 2020, , 351-370.		1
78	Aberrant limbic brain structures in young individuals at risk for mental illness. Psychiatry and Clinical Neurosciences, 2020, 74, 294-302.	1.0	14
79	A mobile-based app to monitor social functioning among youth at-risk for psychosis: Single-arm feasibility and acceptability study. General Hospital Psychiatry, 2020, 67, 148-149.	1.2	1
80	Deficits in auditory predictive coding in individuals with the psychosis risk syndrome: Prediction of conversion to psychosis.. Journal of Abnormal Psychology, 2020, 129, 599-611.	2.0	15
81	Negative Symptoms and Functioning in Youth at Risk of Psychosis: A Systematic Review and Meta-analysis. Harvard Review of Psychiatry, 2020, 28, 341-355.	0.9	22
82	Development and Usability Testing of SOMO, a Mobile-Based Application to Monitor Social Functioning for Youth at Clinical High-Risk for Psychosis. Digital Psychology, 2020, 1, 4-19.	2.0	3
83	Interventions and Transition in Youth at Risk of Psychosis. Journal of Clinical Psychiatry, 2020, 81, .	1.1	30
84	Early Psychosis Intervention-Spreading Evidence-based Treatment (EPI-SET): protocol for an effectiveness-implementation study of a structured model of care for psychosis in youth and emerging adults. BMJ Open, 2020, 10, e034280.	0.8	3
85	Interventions and social functioning in youth at risk of psychosis: A systematic review and meta†analysis. Microbial Biotechnology, 2019, 13, 169-180.	0.9	65
86	Implementation and fidelity assessment of the NAVIGATE treatment program for first episode psychosis in a multi-site study. Schizophrenia Research, 2019, 204, 271-281.	1.1	31
87	Neurocognitive profiles in the prodrome to psychosis in NAPLS-1. Schizophrenia Research, 2019, 204, 311-319.	1.1	30
88	Treatment History of Youth At-Risk for Serious Mental Illness. Canadian Journal of Psychiatry, 2019, 64, 145-154.	0.9	8
89	Attenuated psychotic symptom interventions in youth at risk of psychosis: A systematic review and meta†analysis. Microbial Biotechnology, 2019, 13, 3-17.	0.9	63
90	Association Between P300 Responses to Auditory Oddball Stimuli and Clinical Outcomes in the Psychosis Risk Syndrome. JAMA Psychiatry, 2019, 76, 1187.	6.0	59

#	Article	IF	Citations
91	Metacognition in youth at-risk for psychosis. Schizophrenia Research, 2019, 210, 303-305.	1.1	0
92	O33. EEG Alpha Event-Related Desynchronization Deficits Predict Conversion to Psychosis in Individuals With the Psychosis Risk Syndrome. Biological Psychiatry, 2019, 85, S119.	0.7	4
93	Sleep problems and attenuated psychotic symptoms in youth at clinical high-risk for psychosis. Psychiatry Research, 2019, 282, 112492.	1.7	24
94	S102. COGNITIVE-BEHAVIORAL SOCIAL SKILLS TRAINING IN YOUTH AT CLINICAL HIGH RISK FOR PSYCHOSIS: QUANTITATIVE AND QUALITATIVE METHODS: FOR IMPLEMENTATION AND FACILITATOR TRAINING. Schizophrenia Bulletin, 2019, 45, S345-S346.	2.3	2
95	Clinical staging for youth atâ€risk for serious mental illness. Microbial Biotechnology, 2019, 13, 1416-1423.	0.9	42
96	Multidisciplinary Treatment for Individuals at Clinical High Risk of Developing Psychosis. Current Treatment Options in Psychiatry, 2019, 6, 1-16.	0.7	25
97	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. Frontiers in Psychiatry, 2019, 10, 345.	1.3	29
98	Cortical abnormalities in youth at clinical high-risk for psychosis: Findings from the NAPLS2 cohort. NeuroImage: Clinical, 2019, 23, 101862.	1.4	48
99	Testing a deep convolutional neural network for automated hippocampus segmentation in a longitudinal sample of healthy participants. NeuroImage, 2019, 197, 589-597.	2.1	24
100	Predictors of Transition to Psychosis in Individuals at Clinical High Risk. Current Psychiatry Reports, 2019, 21, 39.	2.1	51
101	Clinical Profiles and Conversion Rates Among Young Individuals With Autism Spectrum Disorder Who Present to Clinical High Risk for Psychosis Services. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 582-588.	0.3	38
102	Impact of childhood adversity on corticolimbic volumes in youth at clinical high-risk for psychosis. Schizophrenia Research, 2019, 213, 48-55.	1.1	21
103	Adding a neuroanatomical biomarker to an individualized risk calculator for psychosis: A proof-of-concept study. Schizophrenia Research, 2019, 208, 41-43.	1.1	15
104	Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis. Psychological Medicine, 2019, 49, 1670-1677.	2.7	74
105	Altered Brain Activation During Memory Retrieval Precedes and Predicts Conversion to Psychosis in Individuals at Clinical High Risk. Schizophrenia Bulletin, 2019, 45, 924-933.	2.3	14
106	The Global Functioning: Social and Role Scalesâ€"Further Validation in a Large Sample of Adolescents and Young Adults at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2019, 45, 763-772.	2.3	55
107	Tobacco use and psychosis risk in persons at clinical high risk. Microbial Biotechnology, 2019, 13, 1173-1181.	0.9	11
108	Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Brain, Behavior, and Immunity, 2019, 76, 268-274.	2.0	48

#	Article	IF	Citations
109	The role of a family history of psychosis for youth at clinical high risk of psychosis. Microbial Biotechnology, 2019, 13, 251-256.	0.9	10
110	Changes in symptom content from a clinical high‐risk state to conversion to psychosis. Microbial Biotechnology, 2019, 13, 257-263.	0.9	7
111	Toward Leveraging Human Connectomic Data in Large Consortia: Generalizability of fMRI-Based Brain Graphs Across Sites, Sessions, and Paradigms. Cerebral Cortex, 2019, 29, 1263-1279.	1.6	55
112	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. Journal of Psychiatry and Neuroscience, 2019, 44, 223-236.	1.4	37
113	Identification and Treatment of Youth with Attenuated Psychosis Syndromes: A Canadian Perspective. , 2019, , 187-197.		1
114	Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotent Subgroups. Schizophrenia Bulletin, 2018, 44, 254-263.	2.3	51
115	Latent class cluster analysis of symptom ratings identifies distinct subgroups within the clinical high risk for psychosis syndrome. Schizophrenia Research, 2018, 197, 522-530.	1.1	22
116	Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis. JAMA Psychiatry, 2018, 75, 555.	6.0	516
117	Biofeedback to treat anxiety in young people at clinical high risk for developing psychosis. Microbial Biotechnology, 2018, 12, 694-701.	0.9	22
118	Treatment Precedes Positive Symptoms in North American Adolescent and Young Adult Clinical High Risk Cohort. Journal of Clinical Child and Adolescent Psychology, 2018, 47, 69-78.	2.2	17
119	Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. Schizophrenia Research, 2018, 192, 357-363.	1.1	45
120	Potentially important periods of change in the development of social and role functioning in youth at clinical high risk for psychosis. Development and Psychopathology, 2018, 30, 39-47.	1.4	31
121	Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophrenia Research, 2018, 194, 4-12.	1.1	65
122	Demographic, psychosocial, clinical, and neurocognitive baseline characteristics of Black Americans in the RAISE-ETP study. Schizophrenia Research, 2018, 193, 64-68.	1.1	24
123	Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction. Schizophrenia Bulletin, 2018, 44, 286-296.	2.3	28
124	Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis. Schizophrenia Bulletin, 2018, 44, 807-823.	2.3	62
125	Exploration of clinical high-risk dropouts. Schizophrenia Research, 2018, 195, 579-580.	1.1	15
126	Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia. Schizophrenia Bulletin, 2018, 44, 369-377.	2.3	31

#	Article	IF	Citations
127	Cerebello-thalamo-cortical hyperconnectivity as a state-independent functional neural signature for psychosis prediction and characterization. Nature Communications, 2018, 9, 3836.	5.8	156
128	Digital Trajectories to Care in First-Episode Psychosis. Psychiatric Services, 2018, 69, 1259-1263.	1.1	31
129	Neurocognitive deficits in a transdiagnostic clinical staging model. Psychiatry Research, 2018, 270, 1137-1142.	1.7	17
130	Family functioning in youth at-risk for serious mental illness. Comprehensive Psychiatry, 2018, 87, 17-24.	1.5	16
131	Use of Machine Learning to Determine Deviance in Neuroanatomical Maturity Associated With Future Psychosis in Youths at Clinically High Risk. JAMA Psychiatry, 2018, 75, 960.	6.0	114
132	The relation of atypical antipsychotic use and stress with weight in individuals at clinical high risk for psychosis. Stress and Health, 2018, 34, 591-600.	1.4	3
133	Youth at-risk for serious mental illness: methods of the PROCAN study. BMC Psychiatry, 2018, 18, 219.	1.1	29
134	Age-related trajectories of social cognition in youth at clinical high risk for psychosis: An exploratory study. Schizophrenia Research, 2018, 201, 130-136.	1.1	13
135	Networks of blood proteins in the neuroimmunology of schizophrenia. Translational Psychiatry, 2018, 8, 112.	2.4	16
136	Pilot study of cognitive remediation and motivational interviewing in youth at risk of serious mental illness. Microbial Biotechnology, 2018, 12, 1193-1197.	0.9	4
137	Anxiety in youth at clinical high risk for psychosis. Microbial Biotechnology, 2017, 11, 480-487.	0.9	56
138	Mapping structural covariance networks of facial emotion recognition in early psychosis: A pilot study. Schizophrenia Research, 2017, 189, 146-152.	1.1	14
139	Ventricular enlargement and progressive reduction of cortical gray matter are linked in prodromal youth who develop psychosis. Schizophrenia Research, 2017, 189, 169-174.	1.1	32
140	The Role of microRNA Expression in Cortical Development During Conversion to Psychosis. Neuropsychopharmacology, 2017, 42, 2188-2195.	2.8	12
141	Multisite reliability of MR-based functional connectivity. NeuroImage, 2017, 146, 959-970.	2.1	140
142	Perceived Autonomy Support in the NIMH RAISE Early Treatment Program. Psychiatric Services, 2017, 68, 916-922.	1.1	15
143	Comorbid diagnoses for youth at clinical high risk of psychosis. Schizophrenia Research, 2017, 190, 90-95.	1.1	95
144	Testing the feasibility of a computerized facial affect recognition training in early psychosis. Schizophrenia Research, 2017, 190, 180-181.	1.1	0

#	Article	IF	Citations
145	Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. Schizophrenia Research, 2017, 185, 167-172.	1.1	29
146	Perceptual abnormalities in clinical high risk youth and the role of trauma, cannabis use and anxiety. Psychiatry Research, 2017, 258, 462-468.	1.7	6
147	Canadian Treatment Guidelines for Individuals at Clinical High Risk of Psychosis. Canadian Journal of Psychiatry, 2017, 62, 656-661.	0.9	50
148	23. Omega-3 Fatty Acid Versus Placebo in a Clinical High-Risk Sample From the North American Prodrome Longitudinal Studies (NAPLS) Consortium. Schizophrenia Bulletin, 2017, 43, S16-S16.	2.3	26
149	Confirmatory factor analysis of the quality of life scale and new proposed factor structure for the quality of life scale-revised. Schizophrenia Research, 2017, 181, 117-123.	1.1	17
150	The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms. Schizophrenia Bulletin, 2017, 43, 57-63.	2.3	84
151	A pilot study of cognitive insight and structural covariance in first-episode psychosis. Schizophrenia Research, 2017, 179, 91-96.	1.1	19
152	SU127. Negative Symptoms in Youth at Clinical High Risk of Psychosis. Schizophrenia Bulletin, 2017, 43, S207-S207.	2.3	2
153	SU127. Negative Symptoms in Youth at Clinical High Risk of Psychosis. Schizophrenia Bulletin, 2017, 43, S207-S208.	2.3	4
154	Resilience in individuals at clinical high risk for psychosis. Microbial Biotechnology, 2016, 10, 212-219.	0.9	29
155	An Individualized Risk Calculator for Research in Prodromal Psychosis. American Journal of Psychiatry, 2016, 173, 980-988.	4.0	458
156	The relations of age and pubertal development with cortisol and daily stress in youth at clinical risk for psychosis. Schizophrenia Research, 2016, 172, 29-34.	1.1	15
157	Traumatic brain injury in individuals at clinical high risk for psychosis. Schizophrenia Research, 2016, 174, 77-81.	1.1	12
158	Core Schemas in Youth at Clinical High Risk for Psychosis. Behavioural and Cognitive Psychotherapy, 2016, 44, 203-213.	0.9	25
159	Functional Capacity Assessed by the Map Task in Individuals at Clinical High-Risk for Psychosis. Schizophrenia Bulletin, 2016, 42, 1234-1242.	2.3	17
160	Association of Neurocognition With Transition to Psychosis. JAMA Psychiatry, 2016, 73, 1239.	6.0	205
161	The Violent Content in Attenuated Psychotic Symptoms. Psychiatry Research, 2016, 242, 61-66.	1.7	14
162	Relation between cannabis use and subcortical volumes in people at clinical high risk of psychosis. Psychiatry Research - Neuroimaging, 2016, 254, 3-9.	0.9	8

#	Article	IF	Citations
163	The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. Schizophrenia Bulletin, 2016, 42, 732-743.	2.3	183
164	Social cognition over time in individuals at clinical high risk for psychosis: Findings from the NAPLS-2 cohort. Schizophrenia Research, 2016, 171, 176-181.	1.1	55
165	Cost-Effectiveness of Comprehensive, Integrated Care for First Episode Psychosis in the NIMH RAISE Early Treatment Program. Schizophrenia Bulletin, 2016, 42, 896-906.	2.3	111
166	Cognitive insight is associated with cortical thickness in first-episode psychosis. Schizophrenia Research, 2016, 172, 16-22.	1.1	24
167	Intensive community outreach for those at ultra high risk of psychosis: dilution, not solution. Lancet Psychiatry,the, 2016, 3, 18.	3.7	26
168	Healthy adolescent performance on the MATRICS Consensus Cognitive Battery (MCCB): Developmental data from two samples of volunteers. Schizophrenia Research, 2016, 172, 106-113.	1.1	20
169	Early traumatic experiences, perceived discrimination and conversion to psychosis in those at clinical high risk for psychosis. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 497-503.	1.6	60
170	Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk. JAMA Psychiatry, 2016, 73, 113.	6.0	354
171	Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. American Journal of Psychiatry, 2016, 173, 362-372.	4.0	601
172	Personal Beliefs about Experiences in those at Clinical High Risk for Psychosis. Behavioural and Cognitive Psychotherapy, 2015, 43, 669-675.	0.9	12
173	At risk or not at risk? A meta‐analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry, 2015, 14, 322-332.	4.8	209
174	Screening tools for clinical high risk for psychosis. Microbial Biotechnology, 2015, 9, 345-356.	0.9	60
175	Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis. BMC Psychiatry, 2015, 15, 276.	1.1	18
176	Exercise practices in individuals at clinical high risk of developing psychosis. Microbial Biotechnology, 2015, 9, 284-291.	0.9	21
177	North American Prodrome Longitudinal Study (NAPLS 2). Journal of Nervous and Mental Disease, 2015, 203, 328-335.	0.5	189
178	Negative symptoms and impaired social functioning predict later psychosis in <scp>L</scp>atino youth at clinical high risk in the <scp>N</scp>orth <scp>A</scp>merican prodromal longitudinal studies consortium. Microbial Biotechnology, 2015, 9, 467-475.	0.9	26
179	Prodromal Symptom Severity Predicts Accelerated Gray Matter Reduction and Third Ventricle Expansion among Clinically High-Risk Youth Developing Psychotic Disorders. Molecular Neuropsychiatry, 2015, 1, 13-22.	3.0	27
180	Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis. Psychiatry Research, 2015, 230, 878-884.	1.7	13

#	Article	IF	Citations
181	Meta-cognition is associated with cortical thickness in youth at clinical high risk of psychosis. Psychiatry Research - Neuroimaging, 2015, 233, 418-423.	0.9	19
182	Theory of mind, emotion recognition and social perception in individuals at clinical high risk for psychosis: Findings from the NAPLS-2 cohort. Schizophrenia Research: Cognition, 2015, 2, 133-139.	0.7	46
183	Reliability of an fMRI paradigm for emotional processing in a multisite longitudinal study. Human Brain Mapping, 2015, 36, 2558-2579.	1.9	63
184	The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components. Psychiatric Services, 2015, 66, 680-690.	1.1	179
185	Duration of Untreated Psychosis in Community Treatment Settings in the United States. Psychiatric Services, 2015, 66, 753-756.	1.1	100
186	Association of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk. JAMA Psychiatry, 2015, 72, 882.	6.0	284
187	Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2015, 41, 1066-1075.	2.3	71
188	Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. Schizophrenia Bulletin, 2015, 41, 1237-1247.	2.3	45
189	Severity of thought disorder predicts psychosis in persons at clinical high-risk. Schizophrenia Research, 2015, 169, 169-177.	1.1	43
190	Association of a Schizophrenia Risk Variant at the *DRD2* Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophrenia Bulletin, 2015, 41, 1248-1255.	2.3	64
191	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophrenia Bulletin, 2015, 41, 1227-1236.	2.3	100
192	Demographic correlates of attenuated positive psychotic symptoms. Schizophrenia Research, 2015, 166, 31-36.	1.1	17
193	Patterns of premorbid functioning in individuals at clinical high risk of psychosis. Schizophrenia Research, 2015, 169, 209-213.	1.1	22
194	Progressive Reduction in Cortical Thickness as Psychosis Develops: A Multisite Longitudinal Neuroimaging Study of Youth at Elevated Clinical Risk. Biological Psychiatry, 2015, 77, 147-157.	0.7	516
195	Psychosocial Treatments for Clinical High Risk Individuals. Schizophrenia Bulletin, 2015, 41, 22-22.	2.3	6
196	Pilot study of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Psychiatry Research, 2015, 225, 93-98.	1.7	56
197	Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results From the NAPLS Project. Schizophrenia Bulletin, 2015, 41, 419-428.	2.3	195
198	Perceived discrimination in those at clinical high risk for psychosis. Microbial Biotechnology, 2014, 8, 77-81.	0.9	27

#	Article	IF	Citations
199	The Relationship of Neurocognition and Negative Symptoms to Social and Role Functioning Over Time in Individuals at Clinical High Risk in the First Phase of the North American Prodrome Longitudinal Study. Schizophrenia Bulletin, 2014, 40, 1452-1461.	2.3	137
200	Metacognitive Functioning in Individuals at Clinical High Risk for Psychosis. Behavioural and Cognitive Psychotherapy, 2014, 42, 526-534.	0.9	24
201	Reliability of neuroanatomical measurements in a multisite longitudinal study of youth at risk for psychosis. Human Brain Mapping, 2014, 35, 2424-2434.	1.9	76
202	Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders. JAMA Psychiatry, 2014, 71, 1350.	6.0	318
203	Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. Schizophrenia Research, 2014, 156, 277-280.	1.1	34
204	Substance use in clinical high risk for psychosis: a review of the literature. Microbial Biotechnology, 2014, 8, 104-112.	0.9	84
205	Development and preliminary validation of the First Episode Social Functioning Scale for early psychosis. Psychiatry Research, 2014, 216, 412-417.	1.7	35
206	Functional development in clinical high risk youth: Prediction of schizophrenia versus other psychotic disorders. Psychiatry Research, 2014, 215, 52-60.	1.7	18
207	Stress exposure and sensitivity in the clinical high-risk syndrome: Initial findings from the North American Prodrome Longitudinal Study (NAPLS). Schizophrenia Research, 2014, 160, 104-109.	1.1	66
208	Movement abnormalities predict transitioning to psychosis in individuals at clinical high risk for psychosis. Schizophrenia Research, 2014, 159, 263-266.	1.1	43
209	Current status specifiers for patients at clinical high risk for psychosis. Schizophrenia Research, 2014, 158, 69-75.	1.1	45
210	The content of attenuated psychotic symptoms in those at clinical high risk for psychosis. Psychiatry Research, 2014, 219, 506-512.	1.7	19
211	Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis. Schizophrenia Research, 2014, 153, 64-67.	1.1	76
212	Exercise practices of young people at their first episode of psychosis. Schizophrenia Research, 2014, 152, 311-312.	1.1	14
213	Reliability of functional magnetic resonance imaging activation during working memory in a multi-site study: Analysis from the North American Prodrome Longitudinal Study. NeuroImage, 2014, 97, 41-52.	2.1	48
214	Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis. Psychiatry Research, 2014, 218, 39-43.	1.7	13
215	Family-Focused Treatment for Adolescents and Young Adults at High Risk for Psychosis: Results of a Randomized Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 848-858.	0.3	148
216	Binocular depth perception in individuals at clinical high risk for psychosis: No evidence of dysfunction.. Neuropsychology, 2014, 28, 366-372.	1.0	2

#	Article	IF	Citations
217	Youth at ultra high risk for psychosis: using the Revised Network Episode Model to examine pathways to mental health care. Microbial Biotechnology, 2013, 7, 170-186.	0.9	126
218	Pathways to care for those at clinical high risk of developing psychosis. Microbial Biotechnology, 2013, 7, 80-83.	0.9	29
219	Treatment possibilities for individuals at clinical high risk of psychosis. Microbial Biotechnology, 2013, 7, 155-161.	0.9	9
220	Cortisol Levels and Risk for Psychosis: Initial Findings from the North American Prodrome Longitudinal Study. Biological Psychiatry, 2013, 74, 410-417.	0.7	221
221	Early traumatic experiences in those at clinical high risk for psychosis. Microbial Biotechnology, 2013, 7, 300-305.	0.9	95
222	Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis. Schizophrenia Research, 2013, 150, 542-546.	1.1	47
223	The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. Psychiatry Research, 2013, 206, 195-199.	1.7	25
224	Theory of mind and social judgments in people at clinical high risk of psychosis. Schizophrenia Research, 2013, 150, 498-504.	1.1	34
225	Predictors of a clinical high risk status among individuals with a family history of psychosis. Schizophrenia Research, 2013, 147, 281-286.	1.1	23
226	Sexual dimorphisms and prediction of conversion in the NAPLS psychosis prodrome. Schizophrenia Research, 2013, 144, 43-50.	1.1	54
227	Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011. Schizophrenia Research, 2013, 148, 99-104.	1.1	33
228	The Psychosis High-Risk State. JAMA Psychiatry, 2013, 70, 107.	6.0	1,222
229	Cyberbullying in those at clinical high risk for psychosis. Microbial Biotechnology, 2013, 7, 427-430.	0.9	22
230	Premorbid functional development and conversion to psychosis in clinical high-risk youths. Development and Psychopathology, 2013, 25, 1171-1186.	1.4	75
231	Identifying a Treatable Psychosis-Risk Cohort. Canadian Journal of Psychiatry, 2013, 58, 3-4.	0.9	1
232	Between-site reliability of startle prepulse inhibition across two early psychosis consortia. NeuroReport, 2013, 24, 626-630.	0.6	6
233	The development of the Content of Attenuated Positive Symptoms Codebook for those at clinical high risk of psychosis. Psychosis, 2012, 4, 191-202.	0.4	9
234	Cognitive Behavioral Therapy in Prodromal Psychosis. Current Pharmaceutical Design, 2012, 18, 558-565.	0.9	11

#	Article	IF	Citations
235	North American Prodrome Longitudinal Study (NAPLS 2): Overview and recruitment. Schizophrenia Research, 2012, 142, 77-82.	1.1	235
236	Impact of trauma on attenuated psychotic symptoms. Psychosis, 2012, 4, 203-212.	0.4	37
237	Whither the Attenuated Psychosis Syndrome?. Schizophrenia Bulletin, 2012, 38, 1130-1134.	2.3	85
238	Risk Factors for Psychosis: Impaired Social and Role Functioning. Schizophrenia Bulletin, 2012, 38, 1247-1257.	2.3	206
239	Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Research, 2012, 196, 220-224.	1.7	226
240	Poster #167 EFFECTS OF COGNITIVE REMEDIATION ON COGNITION IN YOUNG PEOPLE AT CLINICAL HIGH RISK OF PSYCHOSIS. Schizophrenia Research, 2012, 136, S245-S246.	1.1	4
241	Predictors of disengagement from treatment in an early psychosis program. Schizophrenia Research, 2012, 136, 7-12.	1.1	87
242	Affect recognition in people at clinical high risk of psychosis. Schizophrenia Research, 2012, 140, 87-92.	1.1	50
243	Prediction and Prevention of Psychosis in Youth at Clinical High Risk. Annual Review of Clinical Psychology, 2012, 8, 269-289.	6.3	163
244	Maladaptive schemas as a mediator between social defeat and positive symptoms in young people at clinical high risk for psychosis. Microbial Biotechnology, 2012, 6, 87-90.	0.9	35
245	Treating young individuals at clinical high risk for psychosis. Microbial Biotechnology, 2012, 6, 60-68.	0.9	27
246	Impact of Trauma on Attenuated Psychotic Symptoms. Psychosis, 2012, 4, 203-212.	0.4	15
247	Cognitive behaviour therapy for schizophrenia. F1000 Medicine Reports, 2012, 4, 6.	2.9	13
248	Social cognition and functional outcome are separate domains in schizophrenia. Schizophrenia Research, 2011, 127, 262-263.	1.1	13
249	A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research, 2011, 125, 54-61.	1.1	209
250	At Clinical High Risk for Psychosis: Outcome for Nonconverters. American Journal of Psychiatry, 2011, 168, 800-805.	4.0	428
251	Social cognition and negative symptoms in psychosis. Psychiatry Research, 2011, 188, 283-285.	1.7	19
252	Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium<subtitle>Relationship to Family History and Conversion to Psychosis</subtitle><alt-title>Neuropsychology of Prodrome to Psychosis</alt-title>. Archives of General Psychiatry, 2010, 67, 578.	13.8	390

#	Article	IF	Citations
253	Social cognition mediates illness-related and cognitive influences on social function in patients with schizophrenia-spectrum disorders. Journal of Psychiatry and Neuroscience, 2010, 35, 49-54.	1.4	84
254	Using the Brief Core Schema Scales with Individuals at Clinical High Risk of Psychosis. Behavioural and Cognitive Psychotherapy, 2009, 37, 227-231.	0.9	56
255	Cognitive‐behavioral therapy for individuals at high risk of developing psychosis. Journal of Clinical Psychology, 2009, 65, 879-890.	1.0	6
256	The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: A naturalistic study of the North American Prodrome Longitudinal Sample. Schizophrenia Research, 2009, 115, 50-57.	1.1	61
257	Validity of the Prodromal Risk Syndrome for First Psychosis: Findings From the North American Prodrome Longitudinal Study. Schizophrenia Bulletin, 2009, 35, 894-908.	2.3	368
258	Three-Year Outcome of Treatment in an Early Psychosis Program. Canadian Journal of Psychiatry, 2009, 54, 626-630.	0.9	16
259	Early detection of psychosis: finding those at clinical high risk. Microbial Biotechnology, 2008, 2, 147-153.	0.9	33
260	Social and cognitive functioning in psychosis. Schizophrenia Research, 2008, 99, 176-181.	1.1	92
261	Social functioning in individuals at clinical high risk for psychosis. Schizophrenia Research, 2008, 99, 119-124.	1.1	219
262	Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research, 2008, 105, 1-9.	1.1	79
263	Outcome after discharge from an early psychosis program. Schizophrenia Research, 2008, 106, 363-366.	1.1	10
264	Symptom remission in first episode patients. Schizophrenia Research, 2008, 106, 281-285.	1.1	44
265	Facial affect recognition in individuals at clinical high risk for psychosis. British Journal of Psychiatry, 2008, 192, 67-68.	1.7	161
266	Assessment of social judgments and complex mental states in the early phases of psychosis. Schizophrenia Research, 2008, 100, 237-241.	1.1	66
267	Prediction of Psychosis in Youth at High Clinical Risk. Archives of General Psychiatry, 2008, 65, 28.	13.8	1,160
268	Models of substance use in adolescents with and without psychosis. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2008, 17, 202-9.	0.7	4
269	EARLY DETECTION AND INTERVENTION FOR PSYCHOSIS: PERSPECTIVES FROM NORTH AMERICA. Clinical Neuropsychiatry, 2008, 5, 263-272.	0.0	5
270	North American Prodrome Longitudinal Study: A Collaborative Multisite Approach to Prodromal Schizophrenia Research. Schizophrenia Bulletin, 2007, 33, 665-672.	2.3	258

#	Article	IF	Citations
271	The association of insight with psychotic symptoms, depression, and cognition in early psychosis: A 3-year follow-up. Schizophrenia Research, 2007, 89, 123-128.	1.1	90
272	Performance measures for evaluating services for people with a first episode of psychosis. Microbial Biotechnology, 2007, 1, 157-167.	0.9	11
273	The promise of early intervention. Microbial Biotechnology, 2007, 1, 294-307.	0.9	58
274	Early intervention for psychosis: Who refers?. Schizophrenia Research, 2006, 84, 176-177.	1.1	14
275	Facial affect recognition: A mediator between cognitive and social functioning in psychosis?. Schizophrenia Research, 2006, 85, 142-150.	1.1	294
276	Diagnostic stability over one year in first-episode psychosis. Schizophrenia Research, 2006, 86, 71-75.	1.1	63
277	Substance misuse and cognitive functioning in early psychosis: A 2 year follow-up. Schizophrenia Research, 2006, 88, 187-191.	1.1	49
278	Influence of social perception and social knowledge on cognitive and social functioning in early psychosis. British Journal of Psychiatry, 2006, 189, 373-378.	1.7	139
279	Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal of Psychiatry, 2006, 163, 790-799.	4.0	500
280	Cannabis use increases the risk of young people developing psychotic symptoms, particularly if already predisposed. Evidence-Based Mental Health, 2005, 8, 87-87.	2.2	1
281	Clinical Trials During the Prodromal Stage of Schizophrenia. American Journal of Psychiatry, 2005, 162, 1387-1387.	4.0	17
282	Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. Psychiatry Research, 2005, 133, 35-43.	1.7	90
283	The role of family work in early psychosis. Schizophrenia Research, 2005, 79, 77-83.	1.1	94
284	Three-year outcome of family work in an early psychosis program. Schizophrenia Research, 2005, 79, 107-116.	1.1	89
285	The course of cognitive functioning in first episode psychosis: Changes over time and impact on outcome. Schizophrenia Research, 2005, 78, 35-43.	1.1	138
286	Substance misuse at presentation to an early psychosis program. Social Psychiatry and Psychiatric Epidemiology, 2004, 39, 69-72.	1.6	156
287	The Diagnosis and Assessment of Individuals Prodromal for Schizophrenic Psychosis. CNS Spectrums, 2004, 9, 588-594.	0.7	22
288	Cognitive functioning in first episode psychosis: initial presentation. Schizophrenia Research, 2003, 62, 59-64.	1.1	112

#	Article	IF	Citations
289	Patterns of premorbid functioning in first-episode psychosis: initial presentation. Schizophrenia Research, 2003, 62, 23-30.	1.1	71
290	Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry, 2003, 54, 453-464.	0.7	194
291	Symptom Outcome 1 Year after Admission to an Early Psychosis Program. Canadian Journal of Psychiatry, 2003, 48, 204-207.	0.9	84
292	Weight Gain in First-Episode Psychosis. Canadian Journal of Psychiatry, 2003, 48, 272-276.	0.9	36
293	Substance use and cognition in early psychosis. Journal of Psychiatry and Neuroscience, 2003, 28, 48-54.	1.4	88
294	The prodromal stage of psychotic illness: observation, detection or intervention?. Journal of Psychiatry and Neuroscience, 2003, 28, 93-7.	1.4	24
295	Assessment of premorbid function in first-episode schizophrenia: modifications to the Premorbid Adjustment Scale. Journal of Psychiatry and Neuroscience, 2002, 27, 92-101.	1.4	85
296	Cognitive functioning in first-episode schizophrenia. Journal of Psychiatry and Neuroscience, 2002, 27, 188-92.	1.4	54
297	Neurocognitive and social functioning in schizophrenia and other diagnoses. Schizophrenia Research, 2001, 48, 367-368.	1.1	23
298	Social Functioning in First- and Multiepisode Schizophrenia. Canadian Journal of Psychiatry, 2001, 46, 746-749.	0.9	63
299	Impact of an early psychosis program on substance use.. Psychiatric Rehabilitation Journal, 2001, 25, 60-67.	0.8	59
300	Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophrenia Research, 2000, 44, 47-56.	1.1	230
301	Attributional Style and Depression in Schizophrenia. Canadian Journal of Psychiatry, 1999, 44, 697-700.	0.9	12
302	Using Measures of Readiness to Change in Individuals with Schizophrenia. American Journal of Drug and Alcohol Abuse, 1999, 25, 151-161.	1.1	19
303	Facial affect recognition and information processing in schizophrenia and bipolar disorder. Schizophrenia Research, 1998, 32, 171-181.	1.1	407
304	Depression in people with first-episode schizophrenia. British Journal of Psychiatry, 1998, 172, 90-92.	1.7	282
305	Group Treatment for Substance Abuse in Schizophrenia. Canadian Journal of Psychiatry, 1998, 43, 843-845.	0.9	21
306	Effect of substance misuse in early psychosis. British Journal of Psychiatry, 1998, 172, 134-136.	1.7	108

#	Article	IF	Citations
307	Readiness to Stop Smoking in Schizophrenia. Canadian Journal of Psychiatry, 1997, 42, 49-52.	0.9	100
308	Attentional vulnerability indicators in schizophrenia and bipolar disorder. Schizophrenia Research, 1997, 23, 197-204.	1.1	103
309	Treatment of substance abusers: single or mixed gender programs?. Addiction, 1997, 92, 805-812.	1.7	106
310	A psychometric comparison of the Calgary depression scale for schizophrenia and the Hamilton depression rating scale. Schizophrenia Research, 1996, 19, 205-212.	1.1	193
311	Mentally Retarded Patients on General Hospital Psychiatric Units. Canadian Journal of Psychiatry, 1993, 38, 134-136.	0.9	27
312	Assessing Depression in Schizophrenia: The Calgary Depression Scale. British Journal of Psychiatry, 1993, 163, 39-44.	1.7	901
313	Separation group. Journal for Specialists in Group Work, 1992, 17, 20-28.	0.7	5
314	Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research, 1992, 6, 201-208.	1.1	570
315	Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophrenia Research, 1991, 5, 123-134.	1.1	240
316	A depression rating scale for schizophrenics. Schizophrenia Research, 1990, 3, 247-251.	1.1	1,090
317	Treatment Targets in the Pre-psychotic Phase. , 0, , 75-91.		0